ALLMedicine™ Leukemias Center

Mar 6th, 2021 - Cancerous inhibitor of PP2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56a. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2Asplicing variant, NOCIVA (NOvel CIp2a VAriant). Charac...

Mar 6th, 2021 - Tens of millions of individuals go to gasoline stations on a daily basis in the United States. One of the constituents of gasoline is benzene, a Group 1 carcinogen that has been strongly linked to both occupational and non-occupational leukemias. ...

Mar 3rd, 2021 - RUNX1 familial platelet disorder with associated myeloid malignancies (RUNX1-FPDMM) is characterized by prolonged bleeding and/or easy bruising and an increased risk of developing a hematologic malignancy. RUNX1-FPDMM is characterized by thrombocy...

Feb 23rd, 2021 - Genes encoding B lineage restricted transcription factors are frequently mutated in B-lymphoid leukemias, suggesting a close link between normal and malignant B-cell development. One of these transcription factors is Early B cell Factor 1 (EBF1), ...

Feb 16th, 2021 - FLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Curiously...

Jun 25th, 2020

Jun 30th, 2019 - Acute myeloid leukemias (AMLs) are a heterogeneous group of disorders characterized by the clonal expansion of myeloid blasts (eg, undifferentiated myeloid precursors) in the peripheral blood, bone marrow, and/or other tissues, which results in im...

Jun 14th, 2019 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for ...

Feb 27th, 2019 - Now in its 23rd year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies the practical tools to translate emerging data into the bes...

Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.

Mar 6th, 2021 - Cancerous inhibitor of PP2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56a. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2Asplicing variant, NOCIVA (NOvel CIp2a VAriant). Charac...

Mar 6th, 2021 - Tens of millions of individuals go to gasoline stations on a daily basis in the United States. One of the constituents of gasoline is benzene, a Group 1 carcinogen that has been strongly linked to both occupational and non-occupational leukemias. ...

Mar 3rd, 2021 - RUNX1 familial platelet disorder with associated myeloid malignancies (RUNX1-FPDMM) is characterized by prolonged bleeding and/or easy bruising and an increased risk of developing a hematologic malignancy. RUNX1-FPDMM is characterized by thrombocy...

Feb 23rd, 2021 - Genes encoding B lineage restricted transcription factors are frequently mutated in B-lymphoid leukemias, suggesting a close link between normal and malignant B-cell development. One of these transcription factors is Early B cell Factor 1 (EBF1), ...

Feb 16th, 2021 - FLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Curiously...

Jun 25th, 2020

Dec 6th, 2019 - The prospect of an "off-the-shelf" product, rather than one that needs to be grown individually for each patient, is a "very exciting" proposition, say experts discussing new data that will be presented at the forthcoming American Society of Hemat...

Dec 6th, 2019 - The prospect of an "off-the-shelf" product, rather than one that needs to be grown individually for each patient, is a "very exciting" proposition, say experts discussing new data that will be presented at the forthcoming American Society of Hemat...

Oct 7th, 2019 - Click here to access Federal Health Care Cancer Data Trends 2019 Table of Contents Introduction Cancer in the VA: The Big Picture Hepatocellular Carcinoma Prostate Cancer Multiple Myeloma Lung Cancer in the VA at a National Level Lung Cancer – Reg.

Sep 25th, 2019 - (function(n){var r="_ion_ionizer",t=n. getElementsByTagName("script"),i;t=t[t.